Ameriprise
RCUS icon

Ameriprise’s Arcus Biosciences RCUS Stock Holding History

Ameriprise’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.46M Sell
160,082
-65,831
-29% -$1.42M ﹤0.01% 2672
2025
Q4 		$5.38M Buy
225,913
+16,056
+8% +$328K ﹤0.01% 2378
2025
Q3 		$2.85M Buy
209,857
+54,362
+35% +$565K ﹤0.01% 2791
2025
Q2 		$1.27M Sell
155,495
-5,043
-3% -$43.1K ﹤0.01% 3170
2025
Q1 		$1.26M Sell
160,538
-1,387,053
-90% -$16.1M ﹤0.01% 3112
2024
Q4 		$23M Buy
1,547,591
+228,325
+17% +$3.73M 0.01% 1240
2024
Q3 		$20.2M Sell
1,319,266
-155,172
-11% -$2.45M 0.01% 1329
2024
Q2 		$22.5M Buy
1,474,438
+273,417
+23% +$4.41M 0.01% 1204
2024
Q1 		$22.7M Sell
1,201,021
-433,784
-27% -$7.5M 0.01% 1230
2023
Q4 		$31.2M Buy
1,634,805
+54,881
+3% +$877K 0.01% 1006
2023
Q3 		$28.4M Buy
1,579,924
+101,928
+7% +$2.05M 0.01% 1017
2023
Q2 		$30M Buy
1,477,996
+1,282,961
+658% +$24.4M 0.01% 1022
2023
Q1 		$3.56M Sell
195,035
-9,067
-4% -$173K ﹤0.01% 2543
2022
Q4 		$4.22M Sell
204,102
-4,956
-2% -$136K ﹤0.01% 2411
2022
Q3 		$5.47M Buy
209,058
+16,665
+9% +$441K ﹤0.01% 2151
2022
Q2 		$4.88M Buy
+192,393
New +$4.71M ﹤0.01% 2300
2021
Q4 		– Sell
-298,410
Closed -$10.4M – 4035
2021
Q3 		$10.4M Hold
298,410
– – ﹤0.01% 1823
2021
Q2 		$8.2M Sell
298,410
-1,071,985
-78% -$30.6M ﹤0.01% 2088
2021
Q1 		$38.5M Sell
1,370,395
-5,998
-0.4% -$209K 0.01% 896
2020
Q4 		$35.7M Buy
+1,376,393
New +$33.3M 0.01% 897

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ameriprise's RCUS Position: Q1 2026 in Review

Ameriprise reduced its Arcus Biosciences (RCUS) stake by 29% in Q1 2026, selling an estimated $1.42M and leaving 160,082 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2672.

Ameriprise first reported a position in RCUS in Q4 2020 and has held it in 20 quarters since. The position peaked at $38.5M in Q1 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Ameriprise held 160,082 shares of Arcus Biosciences worth $3.46M as of Q1 2026.
  • Ameriprise sold 65,831 Arcus Biosciences shares in Q1 2026, an estimated $1.42M.
  • Arcus Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2672 holding.
  • Ameriprise first reported a position in Arcus Biosciences in Q4 2020 and has held it in 20 quarters since.
  • Ameriprise's Arcus Biosciences position peaked at $38.5M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.